3:11 PM
 | 
Jul 03, 2017
 |  BC Extra  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit an NDA in 1H18 for Acer's lead program Edsivo celiprolol (ACER-002) to treat vascular Ehlers-Danlos syndrome, a collagen production disorder.

Concurrently with the merger,...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >